SG11201806639VA - New streptococcal proteases - Google Patents

New streptococcal proteases

Info

Publication number
SG11201806639VA
SG11201806639VA SG11201806639VA SG11201806639VA SG11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA
Authority
SG
Singapore
Prior art keywords
international
pct
proteases
igg
methods
Prior art date
Application number
SG11201806639VA
Other languages
English (en)
Inventor
Pawel-Rammingen Ulrich Von
Christian Spoerry
Original Assignee
Genovis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57995190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201806639V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genovis Ab filed Critical Genovis Ab
Publication of SG11201806639VA publication Critical patent/SG11201806639VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641Cysteine endopeptidases (3.4.22)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201806639VA 2016-02-04 2017-02-03 New streptococcal proteases SG11201806639VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1630021 2016-02-04
PCT/EP2017/052463 WO2017134274A1 (en) 2016-02-04 2017-02-03 New streptococcal proteases

Publications (1)

Publication Number Publication Date
SG11201806639VA true SG11201806639VA (en) 2018-09-27

Family

ID=57995190

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806639VA SG11201806639VA (en) 2016-02-04 2017-02-03 New streptococcal proteases

Country Status (13)

Country Link
US (1) US12006530B2 (https=)
EP (1) EP3411389B1 (https=)
JP (2) JP7123801B2 (https=)
KR (1) KR102704583B1 (https=)
CN (1) CN109311951B (https=)
AU (1) AU2017214441B2 (https=)
CA (1) CA3013527C (https=)
DK (1) DK3411389T3 (https=)
ES (1) ES2877754T3 (https=)
PL (1) PL3411389T3 (https=)
PT (1) PT3411389T (https=)
SG (1) SG11201806639VA (https=)
WO (1) WO2017134274A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12546782B2 (en) 2013-03-15 2026-02-10 Mayo Foundation For Medical Education And Research Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
AU2017325022B2 (en) 2016-09-07 2022-10-13 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
CN111183220B (zh) 2017-05-26 2024-03-22 杰诺维斯公司 用于聚糖分析的工具
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
EP3723794A1 (en) * 2017-12-15 2020-10-21 Intervet International B.V. A vaccine for protection against streptococcus suis
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
JP2023514204A (ja) 2020-02-14 2023-04-05 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Cdkl5欠損障害を処置するための遺伝子治療
GB202002072D0 (en) * 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
WO2021254479A1 (zh) * 2020-06-18 2021-12-23 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
US20240271115A1 (en) * 2021-06-15 2024-08-15 The University Of North Carolina At Chapel Hill Methods and compositions for depleting antibodies
US20250019721A1 (en) 2021-08-11 2025-01-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
US20240424077A1 (en) * 2021-11-18 2024-12-26 Intervet Inc. A method to produce a vaccine against streptococcus suis and the said vaccine
JPWO2024111657A1 (https=) * 2022-11-25 2024-05-30
JPWO2025047641A1 (https=) * 2023-08-25 2025-03-06
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
JP2008525033A (ja) 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド B群連鎖球菌
PL1901773T3 (pl) 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
DK2190984T3 (da) 2007-09-14 2013-12-02 Genovis Ab Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases

Also Published As

Publication number Publication date
JP2022115853A (ja) 2022-08-09
PT3411389T (pt) 2021-06-28
CN109311951A (zh) 2019-02-05
CA3013527C (en) 2023-09-05
JP2019506866A (ja) 2019-03-14
KR102704583B1 (ko) 2024-09-06
US20190345533A1 (en) 2019-11-14
DK3411389T3 (da) 2021-06-21
AU2017214441B2 (en) 2021-08-19
ES2877754T3 (es) 2021-11-17
US12006530B2 (en) 2024-06-11
EP3411389A1 (en) 2018-12-12
JP7123801B2 (ja) 2022-08-23
CN109311951B (zh) 2022-10-11
KR20180124857A (ko) 2018-11-21
EP3411389B1 (en) 2021-03-24
WO2017134274A1 (en) 2017-08-10
CA3013527A1 (en) 2017-08-10
AU2017214441A1 (en) 2018-08-16
PL3411389T3 (pl) 2021-10-25

Similar Documents

Publication Publication Date Title
SG11201806639VA (en) New streptococcal proteases
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201909949XA (en) Targeted immunotolerance
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811405QA (en) Improved differentiation method
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811432WA (en) Rna for cancer therapy
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201909957TA (en) Engineered ligase variants
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201811169WA (en) Methods and systems for recommending to a first user media assets for inclusion in a playlist for a second user based on the second user's viewing activity
SG11201803765TA (en) Systems and methods for processing loyalty rewards
SG11201906663VA (en) Bone-targeting antibodies
SG11201908326YA (en) Methods of treating neurodegenerative diseases